Risperdal Male Breast Growth Lawsuit Settles as Trial Begins

Johnson & Johnson agreed to settle a Risperdal lawsuit this week, resolving a case that claimed their antipsychotic drugs can cause substantial male breast growth. 

The settlement came as trial was about to begin for a lawsuit brought by 21-year-old Aaron Banks, who alleged that he grew breast due to Risperdal side effects, causing him to suffer psychological trauma and undergo surgery to have the breasts removed.

Banks’ case was the first of several dozen Risperdal male breast growth lawsuits that was scheduled to reach a jury. Some of the cases also involved use of the schizophrenia medication Invega, which contains the primary active metabolite of Risperdal.

Learn More About

Risperdal Lawsuits

Side effects of Risperdal linked to risk of breast growth among young boys, or gynecomastia.

Learn More About this Lawsuit SEE IF YOU QUALIFY FOR COMPENSATION

The complaints all involve similar allegations that Johnson & Johnson’s Janssen Pharmaceutica subsidiary failed to adequately warn about the risk of breast growth among teen boys given the antipsychotic medications.

Side effects of Risperdal and Invega increase the risk that boys may experience dramatic breast growth, according to allegations raised in the complaints. In some cases, boys grew breasts measuring as large as a 38D cup after using the medications.

Risperdal also increases the risk of significant weight gain, and in many cases doctors initially miss or dismiss signs of male breast growth, assuming it is connected to increases in weight. However, surgical breast removal or reduction may be necessary in some cases due to the unnatural growth.

While Risperdal currently carries a warning that unusual breast growth could be a side effect of the medication, the lawsuits allege that the risks were not properly emphasized and that manufacturers downplayed the severity and numbers involved. According to prescribing information packaged with the drug, 2.3% of adolescents in clinical trials experienced breast growth due to elevated levels of the hormone prolactin.

Most of the cases filed throughout the United States are pending in the Philadelphia Court of Common Pleas, which had scheduled the Banks’ lawsuit to serve as a “bellwether” trial, to help the parties gauge how juries are likely to respond to evidence and testimony that may be repeated throughout many cases. The Risperdal settlement was announced on the first day of the scheduled trial, but no details have been released about the terms of the agreement.

1 Comments

  • albertJanuary 28, 2013 at 11:12 pm

    i spent 17 months in the orange county jail,orlando,fl and all the time took resperdal for my mental illness and my brest grew to the size of a peach and im verv embaressed to take my shirt off in public or in front of my wife.im thinking on a brest reduction.this is very emberessing to me.what can i do in sueing for damages.i acidently saw this law suit on tbs tv.can i get some representation.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.